Innovating with Process Intensification and Cutting-Edge Bioprocess Technologies
At Fixell Biotechnology AB, our core technology revolves around process intensification, a transformative platform designed to optimize bioprocess development. This technology is grounded in our deep understanding of complex bioprocesses and our commitment to pushing the boundaries of efficiency, scalability, and productivity in biotechnology evolution.
Our process intensification platform streamlines and enhances the production of biologics, including recombinant proteins, viral vectors, and cell therapies, by integrating advanced process design with cutting-edge engineering. This allows us to deliver higher yields, reduce production costs, and shorten time-to-market for our clients, all while maintaining the highest standards of quality and regulatory compliance.
A patent pending (WO2342035) proprietary technology provides a novel approach to the production of viral vectors, which are key components in gene therapy, vaccine development, and other advanced therapeutic applications. With this technology, we aim to significantly improve the efficiency, scalability, and purity of viral vector production, addressing one of the major bottlenecks in the industry and providing our customers with a competitive edge in the rapidly evolving field of gene therapies.
By combining our deep scientific expertise with our passion for innovation, Fixell Biotechnology is positioning itself as a leader in the development of next-generation biomanufacturing technologies. Whether you are looking to optimize your existing processes or develop entirely new bioproducts, we offer the expertise and solutions to accelerate your success.